Scl-70 Antibody (Anti-Topoisomerase)

Anti-topoisomerase I (anti‑Scl‑70) antibodies are autoantibodies directed against the nuclear enzyme topoisomerase I. They are a relatively specific blood marker for systemic sclerosis—particularly the diffuse cutaneous subtype—and are found in roughly 20–40% of affected people. Their presence correlates with greater skin involvement, higher risk of interstitial lung disease and pulmonary fibrosis, and generally indicates a more severe disease course.

A positive anti‑Scl‑70 (anti–topoisomerase I) antibody suggests systemic sclerosis, particularly the diffuse cutaneous form. It’s linked to more extensive skin involvement and higher risk of interstitial lung disease or pulmonary fibrosis, implying a potentially more severe course. It’s not diagnostic alone — clinical evaluation, pulmonary function tests, high‑resolution chest CT and rheumatology follow‑up are recommended.

Anti-topoisomerase I (anti–Scl‑70) antibodies are classically associated with systemic sclerosis (scleroderma), particularly the diffuse cutaneous form. Their presence correlates with more extensive skin involvement, increased risk of interstitial lung disease/pulmonary fibrosis, and generally indicates a more severe disease course and poorer prognosis. They support diagnosis and help with risk stratification alongside clinical findings and other autoantibodies.

Yes — Scl‑70 (anti‑topoisomerase I) is strongly associated with systemic sclerosis but can occasionally be detected without clinical scleroderma. A positive result warrants clinical correlation, repeat testing and specialist assessment because it increases the likelihood of developing systemic sclerosis or overlap autoimmune disease. Evaluation typically includes an ANA panel, organ screening (pulmonary, cardiac/renal) and regular follow‑up.

Scleroderma antibodies (for example anticentromere, anti‑topoisomerase I, anti‑RNA polymerase III) mean your immune system is producing autoantibodies associated with systemic sclerosis. Their presence raises suspicion for scleroderma and helps predict disease subtype and organ risks, but isn’t diagnostic alone. A rheumatology evaluation, ongoing symptom monitoring and organ screening (skin, lungs, kidneys) guide further testing and management.

Anti-topoisomerase I (anti‑Scl‑70) is an autoantibody against DNA topoisomerase I and serves as a serologic marker of systemic sclerosis. It is most strongly associated with the diffuse cutaneous subtype and correlates with more extensive skin involvement, a higher risk of interstitial lung disease/pulmonary fibrosis, and generally a more severe disease course.